Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $7.14

Key Points

• Neumora Therapeutics, Inc. has received an average recommendation of "Hold" from analysts, with one sell rating, five holds, and three buy ratings.
• The company's average 12-month price target among analysts is $7.14, despite the stock currently trading around $1.66.
• Neumora is engaged in developing therapies for neurodegenerative diseases and has a promising candidate, navacaprant, currently in phase 3 clinical trials for major depressive disorder.

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average rating of "Hold" from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $7.1429.

Separately, Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th.

Neumora Therapeutics Stock Performance

NMRA traded down $0.04 during trading hours on Tuesday, hitting $1.62. 440,408 shares of the stock were exchanged, compared to its average volume of 338,943. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54. The stock has a market cap of $262.36 million, a price-to-earnings ratio of -1.03 and a beta of 2.92. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $17.19. The stock has a 50-day simple moving average of $1.65 and a 200-day simple moving average of $1.15.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05. Analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors have recently bought and sold shares of the stock. Rafferty Asset Management LLC purchased a new position in Neumora Therapeutics in the 4th quarter worth about $185,000. BNP Paribas Financial Markets purchased a new position in Neumora Therapeutics in the 4th quarter worth about $221,000. Jump Financial LLC purchased a new position in Neumora Therapeutics in the 1st quarter worth about $25,000. CWM LLC increased its stake in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company's stock worth $25,000 after purchasing an additional 24,864 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new position in Neumora Therapeutics in the 4th quarter worth about $281,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.